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In HIV vaccine design, one primary challenge is how to handle the extensive sequence variability in 
circulating viruses. It is uncertain whether the ability to control viral replication depends more on T-
cell responses to a large number of Gag epitope variants, responses to the most highly conserved 
epitopes, or responses to the most commonly occurring variants. Understanding the nature of Gag-
specific T-cell responses that are successful at controlling virus replication would assist in designing 
effective HIV vaccine strategies. A recent paper from the Dr. Nicole Frahm Lab of the Vaccine and 
Infectious Disease Division showed that T-cell responses to the most commonly occurring variants 
contribute more to virologic control than the other factors. 
The researchers compared the nature of T-cell responses between untreated HIV-infected patients 
with or without control of virus replication. The researchers tested for T-cell responses (gamma 
interferon and interleukin-2 FluoroSpot analysis) by cells from the patients using a peptide panel 
spanning the entire Gag protein. This peptide panel contained all epitopes present in at least 5% of 
clade B Gag sequence variants in the Los Alamos National Laboratory HIV Sequence Database. 
Initial analysis revealed similar Gag-specific T-cell responses in HIV controllers and progressors in 
terms of the number of targeted epitopic regions and the targeting of either conserved or highly 
variable regions of Gag. 
Next, the researchers looked at the percent epitope variants in each targeted epitopic region that 
induced a response. Surprisingly, they found marginally higher levels of epitope variant recognition 
per epitopic region in virologic progressors than in controllers (p = 0.05). It was also observed that 
patients whose T-cells recognized more epitope variants had higher viral loads. It is possible that the 
recognition of a larger number of epitope variants could be caused by higher viral loads, which 
provide more exposure to antigens. Supporting this hypothesis, the initiation of antiretroviral 
treatment, and thus a reduction in viral load, resulted in a reduction in epitope variant recognition in 
all 5 subjects put on therapy. 
Finally, the frequency with which each targeted epitope variant appears in the HIV sequence 
database provides a method for identifying the most commonly occurring HIV variants that are 
targeted. The overall proportion of HIV database sequences targeted by a patient's T-cells was 
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defined as the "sequence coverage". Interestingly, sequence coverage was higher in patients with 
controlled viral replication compared to non-controllers (see figure). 
This study is highly relevant to HIV vaccine design according to lead author Dr. Justine Sunshine, a 
postdoctoral fellow in the Frahm Lab. "Several vaccination strategies have been developed to 
overcome the challenges of the extensive sequence diversity present in circulating HIV populations, 
including variant-inclusive vaccines designed to increase epitope variant recognition by T cells," she 
explains. "Our study suggests that it is the ability of T cells to target the most commonly occurring 
variants ("sequence coverage") rather than simply a large number of variants that contributes to 
control of viral replication. Thus, sequence coverage may serve as a possible correlate of protection 
in which to evaluate the protective potential of these new vaccines." 
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Image provided by Dr. Justine Sunshine (Vaccine and Infectious 
Disease Division). 
Median percent sequence coverage was found to correlate with 
control of HIV replication. (Elite controllers (undetectable viral 
load), filled circles; viremic controllers (detectable viral loads of < 
2,000 RNA copies/ml), open circles; progressors (median viral 
loads > 10,000 RNA copies/ml), blue squares.) 
 
